Beihai Biotech

Beihai Biotech is a leading biopharmaceutical company dedicated to revolutionizing healthcare through innovative therapeutics. Our core philosophy is "Putting Patients First, Innovation for All." We possess two innovative technology platforms: 1. Precision Delivery Technology (PDT) platform: Enables precise delivery of therapeutics, maximizing efficacy and minimizing side effects. 2. Peptide-Drug Conjugate (PDC) platform: Combines peptides and small molecule drugs for advanced drug development. With a pipeline of 10 promising drug candidates covering diverse therapeutic indications including Oncology and Pain. Over most advanced asset is BH009 which is branded docetaxel with much better safety profile and efficacy and is in approval stage with US FDA via 505B2 route and expected to get approval soon. We have obtained over 30 patents in major markets worldwide, demonstrating our dedication to pioneering drug development. We believe in the power of scientific innovation. We are steadfast in developing breakthrough therapeutic drugs that are safe, effective, and urgently needed in clinical practice. Our goal is to provide better treatment options for patients worldwide. At Beihai Biotech, we believe in reviving with scientific innovation and putting patients first. Our progress is driven by the clinical value our therapies offer, and we are committed to bringing these therapies to patients in need. Thank you for your interest in Beihai Biotech. If you have any further questions or need more information, please feel free to contact us. Together, let's create a healthier future.